Basic Information

Gene symbol PLK1 Synonyms PLK, STPK13 Type of gene protein-coding
Description polo like kinase 1

GTO ID GTC0212
Trial ID NCT02191878
Disease Hepatocellular Carcinoma
Altered gene PLK1
Therapeutic/Target gene Target gene
TherapysiRNA
Treatment TKM-080301|PLK1 SNALP|TKM-PLK1
PhasePhase1|Phase2
Recruitment statusCompleted
TitleOpen-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Year2014
CountryCanada|China|Korea,Republic of|Singapore|China|United States
Company sponsorArbutus Biopharma Corporation
Other ID(s)TKM-HCC-001
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: TKM-080301_dose level 1
Administration route intravenous injection
Dosage 0.3 mg/kg
Pts 3
Age Child, Adult, Older_Adult
References PMID: 30598500
Cohort2: TKM-080301_dose level 2
Administration route intravenous injection
Dosage 0.6 mg/kg
Pts 9
Age Child, Adult, Older_Adult
References PMID: 30598500
Cohort3: TKM-080301_dose level 3
Administration route intravenous injection
Dosage 0.75 mg/kg
Pts 15
Age Child, Adult, Older_Adult
References PMID: 30598500
Cohort4: TKM-080301_dose level 2_dose expansion at the MTD
Administration route intravenous injection
Dosage 0.6 mg/kg
Pts 16
Age Child, Adult, Older_Adult
Outcome Maximum tolerated dose (MTD):0.6 mg/kg
References PMID: 30598500

Relationship Graph

Overview of Knowledge Graph